Key facts
- This page summarizes James B. Breitmeyer's Form 4 filing for Oncternal Therapeutics, Inc..
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 01 Aug 2022, 18:18.
James B. Breitmeyer - 28 Jul 2022 Form 4 Insider Report for Oncternal Therapeutics, Inc.
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- N/A
- Reported as of
- 28 Jul 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Aug 2022, 18:18:07 UTC
- Prior SEC filing
- 23 Jun 2022
- Next SEC filing
- 05 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/Chase C. Leavitt, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James B. Breitmeyer filed Form 4 for Oncternal Therapeutics, Inc. on 01 Aug 2022.
Change
- Previous filing in this sequence was filed on 23 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ONCT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +185,625
- Change %
- +48%
- Price
- $0.000000
- Shares after
- 569,774
- Date
- 28 Jul 2022
- Ownership
- Direct
- Footnotes
- F1
ONCT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +18,750
- Change %
- +289%
- Price
- $0.000000
- Shares after
- 25,243
- Date
- 28 Jul 2022
- Ownership
- By Spouse
- Footnotes
- F1
ONCT
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 46,544
- Date
- 28 Jul 2022
- Ownership
- By Family Trust
ONCT
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 733
- Date
- 28 Jul 2022
- Ownership
- By Child
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ONCT
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +123,750
- Change %
- Price
- $0.000000
- Shares after
- 123,750
- Date
- 28 Jul 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 123,750
- Exercise price
- $1.04
- Footnotes
- F2
ONCT
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +12,500
- Change %
- Price
- $0.000000
- Shares after
- 12,500
- Date
- 28 Jul 2022
- Ownership
- By Spouse
- Underlying class
- Common Stock
- Underlying amount
- 12,500
- Exercise price
- $1.04
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents an award of restricted stock units (RSUs). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. One half of the RSUs vest on July 3, 2023, and one half of the RSUs vest on January 3, 2024, subject to the Recipient's continued employment or service with the Issuer on each such date. All of the RSUs vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan).
Footnote F2
One half of the shares subject to the stock options vest on July 3, 2023 and one half of the shares subject to the stock options vest on January 3, 2024, subject to the Recipient's continued employment or service with the Issuer on each such date. All of the shares subject to the stock options vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan).